Skip to main
CBAY
CBAY logo

CymaBay Therapeutics (CBAY) Stock Forecast & Price Target

CymaBay Therapeutics (CBAY) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 24%
Hold 47%
Sell 0%
Strong Sell 0%

Bulls say

CymaBay Therapeutics is poised for success due to their strong pipeline of potential treatments for liver and chronic diseases, including the promising seladelpar and MBX-2982. Positive results and planned partnerships for seladelpar, along with a favorable market size for PBC treatment and supportive recommendations from key opinion leaders, suggest that CBAY has the potential for significant growth. However, risks in commercial and regulatory aspects, as well as the number of patients required for their studies, could present challenges for the company.

Bears say

CymaBay Therapeutics is facing significant commercial and competitive risks with its lead product candidates, seladelpar and MBX-2982, in clinical development for liver diseases with high unmet need. The company's cash balance of $438.8 million may only support operations until the first half of 2026, raising concerns about its long-term sustainability and potential need for additional fundraising. In addition, the recent failure of MBX-2982 in a Phase 2a study for type 1 diabetes may further impact investor sentiment and future potential market opportunities for the company's pipeline.

CymaBay Therapeutics (CBAY) has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 24% recommend Buy, 47% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CymaBay Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CymaBay Therapeutics (CBAY) Forecast

Analysts have given CymaBay Therapeutics (CBAY) a Buy based on their latest research and market trends.

According to 17 analysts, CymaBay Therapeutics (CBAY) has a Buy consensus rating as of Jun 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CymaBay Therapeutics (CBAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.